Compare Merck & Co., Inc. (MRK) vs Sun Life Financial Inc. Common Stock (SLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Sun Life Financial Inc. Common Stock — how do they compare? Merck & Co., Inc. trades at $148.85 (market cap $350.29B), while Sun Life Financial Inc. Common Stock trades at $77.62 (market cap $43.10B). The key difference: Merck & Co., Inc. is far larger — about 8.1× Sun Life Financial Inc. Common Stock's market cap, and Sun Life Financial Inc. Common Stock pays the higher dividend (3.48%). Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Sun Life Financial Inc. Common Stock for 0 Days on average.
| MRK | SLF | |
|---|---|---|
Market Cap | $350.29B | $43.10B |
Volume | 8,158,912 | 448,420 |
Sector | Health | Financials |
52-Week High | $156.43 | $84.07 |
52-Week Low | $82.49 | $57.60 |
Typical Hold Time | 98 Days | 0 Days |
Enterprise Value | $397.05B | $44.83B |
Dividend Yield | 2.39% | 3.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $147.37, up 1.32% today, with a bullish technical signal and strong institutional buying. Recent earnings beats and a $6.7 billion acquisition of Terns Pharmaceuticals highlight growth momentum. Revenue reached $65.01 billion in 2025, with net income at $18.25 billion, though the P/E ratio of 113.58 reflects high valuation expectations.
Outlook is positive with a consensus price target of $158.50, but risks include patent expirations, regulatory scrutiny, and integration challenges from acquisitions. The stock's premium valuation requires sustained earnings growth to justify further upside, with investor sentiment bolstered by analyst support and strategic pipeline expansion.
Sun Life Financial (SLF) trades at $77.87, up 0.69% on the day, reflecting steady momentum. The stock shows consistent earnings beats in recent quarters, with Q3 2026 results pending. Financial health is solid, with a P/E of 18.82 and robust cash flow projections for 2026. Recent strategic moves include expanding disability benefits and forming a reinsurance partnership, signaling growth initiatives.
The outlook for SLF is cautiously optimistic, supported by earnings strength and strategic expansions. Key risks include competitive pressures and macroeconomic volatility. Analyst sentiment is mixed, with a majority hold rating, suggesting potential stability but limited near-term upside. Investors should weigh solid fundamentals against sector headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Sun Life Financial Inc. Common Stock
Sun Life Financial Inc. is a Canada-based financial services company providing insurance, wealth and asset management, and health solutions for individuals and institutions. Its products span life, health, and disability insurance along with mutual funds and pension asset management, through operations in Canada, US, the United Kingdom, Ireland, and across Asia.
Read more on SLF →
